From Lab to Real World SolutionsBuilt on more than a decade of research, Mitovation is focused on commercializing its novel infrared light technology poised to address a critical unmet need to prevent reperfusion injury in infant and adult cardiac arrest, stroke, traumatic brain injury (TBI), and neonatal encephalopathy.
Mitovation’s technology was discovered in the lab of Dr. Maik Hüttemann (Wayne State University) and proven effective in multiple in vivo animal models in the lab of Dr. Thomas Sanderson (University of Michigan).
Small animal studies
After initial discovery, the infrared light technology was tested and assessed in small rodent models of cardiac arrest/ resuscitation to confirm safety and efficacy.
Supported by a $6.5 million Cooperative Agreement with the NIH, Mitovation plans to begin its first-in-human clinical trial to assess the safety and effectiveness of its technology to prevent cerebral reperfusion injury following infant cardiac arrest in Q424.
Large animal studies
Following confirmation of neuroprotective benefit in small animal models, Mitovation started studying IRL’s effects in large animals, which are more biologically similar to humans.
Mitovation is currently developing sophisticated computer models to understand the way light passes through human biological tissues.
Mitovation is dedicated to bringing novel technology to the treatment of reperfusion brain injuries. Our goal is to commercialize products that improve short and long term quality of life in children and adults.
What We're Doing
Mitovation is currently conducting grant funded research and developing its product with the help of multiple partners.
Why it Matters
Those who experience different types of brain injuries have poor short and long term outcomes with limited treatment options available to them. Our approach has the potential to address these critical unmet needs and bring value to our healthcare system.
Mitovation’s story began in the labs of Drs. Maik Hüttemann and Thomas Sanderson. Starting in 2006, they sought to understand the ways in which infrared light (IRL) of varying wavelengths interact with subcellular structures called the mitochondria. This work led to the eventual discovery behind Mitovation’s unique technology: that specific wavelengths of infrared light can inhibit sub-cellular reactions in cells that have been reperfused after being denied blood flow and oxygen. This concept was initially confirmed by Drs. Hüttemann and Sanderson in the lab, and has led to testing in small and large animal models of cardiac arrest/resuscitation, ischemic stroke, TBI, and neonatal hypoxia/ischemia. To date, this work has confirmed the neuroprotective effects on the brain of inhibitory wavelengths of IRL. Animals treated with Mitovation therapy have less brain damage and robustly improved neurological functional outcomes as compared to untreated animals.
Drs. Hüttemann and Sanderson founded the company in November of 2016 with the intent to translate this non-invasive, groundbreaking technology to humans. With generous support from multiple granting agencies including the NIH and DoD, Mitovation’s team has been able to continue its ongoing investigation of its technology in multiple animal models, and is designing and developing a commercial product to be used in first-in-human studies in the process of achieving FDA clearance.
Mitovation is currently seeking investment to accelerate the commercialization of our product. For more information, please provide your email below or fill out a form in the Contact section of our website.